In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vertex gets $155mm for deals tied to telaprevir milestones

Executive Summary

Significantly boosting its cash position, Vertex Pharmaceuticals (small molecules for infectious diseases, inflammation, cystic fibrosis, and cancer) has raised $155mm in two separate transactions related to the European milestones that were owed to the company by Janssen, its partner since 2006 on Vertex's Phase III HCV protease inhibitor telaprevir. Instead of paying Vertex, Janssen will now owe the milestone money to four undisclosed investment funds, which have purchased $120mm in Vertex three-year notes that are secured by $155mm in milestones tied to the regulatory filing and approval ($100mm) and launch ($55mm) of the drug in Europe. Further, the funds have paid $35mm for rights to another $95mm in European launch milestones. In addition to a payment from Mitsubishi Tanabe to amend their 2004 telaprevir agreement in Japan and Asia, plus current cash on hand, Vertex expects to have $800mm in cash at the end of this year.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Other

Related Companies